PRME Prime Medicine, Inc.

XNAS 4.30 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

PRME $4.30 —
Key stats
$4.30
52-Week Range
$2.67 – $5.91
YTD
+21.81%
IV Rank (30D)
68.57
Straddle Price
$1.38
P/C Vol Ratio
0.67
Market Cap
$0.8B
Open
$4.68
Day Range
$4.22 – $4.71
Volume
3,508,652
Prev Close
$4.65
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY2.07
Cost of Equity (CAPM)15.76% (VRP-adj)
WACC16.34%
Volatility Risk Premium+7.8pp (IV − HV30), ERP adj +24bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-5.8%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-472.0%
Book / Price4.8%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-3850.9%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$3.65 (Market Anchor value)
SMA 20 / Bollinger Mid$4.12
Bollinger Width / SMA2061.4% (drives anchor stability)
Net Debt$-0.0B
Market Cap$1B
Peers used for multiples: BEAM, CDNA, CRSP, GH, LLY, MRNA, NTRA, TWST
60-Day Conviction
41%
20-Day Fair Value
≈ by Dec 8, 2026
$4.29
α -0.3% rank 38%
conviction
23%
40-Day Fair Value
≈ by Jan 6, 2027
$4.34
α +0.8% rank 25%
conviction
31%
60-Day Fair Value
≈ by Feb 4, 2027
$4.36
α +1.5% rank 22%
conviction
41%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $3.20 17% median 14.3× · 7 peers
Peer P/S $0.42 17% median 18.4× · 8 peers
Market Anchor (SMA50) $3.65 67% stability 78% (BB-width)
Options Expected (B-L 30d) $4.46 0% 8 strikes · skew +0.19
As of 2026-11-09 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.8B
Employees
146
List Date
2022-10-20
CIK
0001894562
Last Earnings
Aug 6 after close · +4.4% vs ±21.2% expected
Headquarters
Cambridge, MA
Homepage
https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin def…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'22'23'24'25'26Avg
Jan--0.23%-27.51%-6.35%7.93%-6.43%
Feb---6.91%28.61%-4.91%21.58%9.59%
Mar---24.72%-19.91%-10.96%-25.32%-20.23%
Apr--14.85%-27.22%-3.08%4.57%-2.72%
May---2.07%22.96%-32.18%4.11%-1.79%
Jun---0.75%-21.53%107.56%8.53%23.45%
Jul--3.93%2.37%37.00%-24.65%4.66%
Aug---10.78%-17.53%-19.80%27.76%-5.09%
Sep---25.35%0.26%77.56%-14.43%9.51%
Oct22.45%-25.74%12.46%-11.63%57.86%11.08%
Nov-18.61%13.08%-18.36%-16.23%-3.15%*-8.65%
Dec12.61%9.93%-15.36%-0.86%--1.58%
Total12.23%-49.90%-65.51%54.89%45.82%-0.49%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $4.16
SMA 50: $3.66
SMA 200: $3.51
Current: $4.30
EMA 12: $4.44
EMA 26: $4.13
MACD: 0.3089 | Signal: -0.0066
BULLISH
ADX (14): 33.20
TREND
+DI: 31.41
−DI: 22.14

Momentum Oscillators

RSI (14): 52.43
NEUTRAL
Stoch %K: 42.95
Stoch %D: 49.07
Williams %R: -63.63

Volume & Volatility

BB Upper: $5.40
BB Lower: $2.91
NEUTRAL
OBV: -18,856,758
Vol SMA 20: 5,300,226
Vol ROC: 38.51%
ATR: $0.46
True Range: $0.49
HV 20: 148.0%
HV 30: 138.6%
HV 60: 117.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis

LLM Stock Analysis Report

SYMBOL: PRME

Executive Summary: Overall assessment: BEARISH with a confidence level of 6/10 Key drivers: Bearish momentum, high volatility, negative news sentiment Primary risks: Potential technical breakdown, increased selling pressure Investment thesis: Short-term bearish trend may continue due to recent technical signals and news sentiment. Recent news sentiment impact: Negative headlines have contributed to the bearish trend.

Technical Analysis: Trend Direction: Bearish in the short-term (1-4 weeks), neutral in the medium-term (1-3 months)

Support/Resistance Levels: Upper Bollinger Band ($3.28) acts as resistance, Lower Bollinger Band ($2.85) serves as support.

Momentum Signals: RSI interpretation: 49.35 is neutral, indicating no clear buy or sell signal. MACD signal: Bearish momentum persists due to the MACD histogram being below zero (-0.09). Bollinger Bands position: The price touching the upper band indicates overbought conditions.

Volume Analysis: Volume rate of change is -14.13%, indicating decreased volume and potential selling pressure.

News & Sentiment Analysis: Recent Headlines Summary: Prime Medicine has received positive news headlines, but recent negative sentiment has dominated. Sentiment Assessment: Overall sentiment is NEUTRAL with a slight lean towards being bearish. Catalyst Identification: Upcoming investor conferences may provide some clarity on the company's future prospects.

Risk & Volatility Assessment: Beta Interpretation: Beta is 2.28, indicating high volatility relative to the market (SPY). Volatility Regime: Current volatility is above historical levels, increasing the risk. Options Market Signals: IV rank is 42.7%, suggesting medium-level volatility and some bullish sentiment.

Market Context & Positioning: Sector Performance: Biotech sector has been weak, affecting Prime Medicine's stock performance. Institutional Activity: Volume patterns suggest institutional interest is waning. Correlation Analysis: The stock moves relatively strongly with the market (R-squared = 0.33).

Key Levels & Action Items: Critical Price Levels: Support at $2.85 and resistance at $3.28. Breakout/Breakdown Levels: A break below $2.85 could signal a deeper bearish trend. Time-Sensitive Catalysts: Upcoming investor conferences may provide some clarity on the company's future prospects. Risk Management: Consider stop-loss levels around $2.90 and position sizing considerations based on recent volatility.

By analyzing the data, I conclude that Prime Medicine (PRME) is currently experiencing a short-term bearish trend driven by high volatility, negative news sentiment, and bearish momentum signals. The stock's beta is 2.28, indicating high volatility relative to the market, which increases the risk. As the company prepares for investor conferences, it may be essential to reassess the situation and adjust positions accordingly.

Generated
News
All PRME news →
Earnings History
13 of 14 under expected move
Avg Expected Move
36.07%
Avg Actual Move
6.21%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-05-11 After-Close 30.68% 1.35% 0.04x Within
2023-08-07 After-Close 19.20% 1.27% 0.07x Within
2023-11-03 After-Close 14.74% 0.51% 0.03x Within
2024-02-14 After-Close 22.29% 13.62% 0.61x Within
2024-05-10 After-Close 14.26% 14.44% 1.01x Exceeded
2024-08-08 After-Close 55.24% 4.44% 0.08x Within
2024-11-12 After-Close 24.31% 8.33% 0.34x Within
2025-02-28 After-Close 25.79% 11.31% 0.44x Within
2025-05-08 After-Close 34.09% 1.52% 0.04x Within
2025-07-30 After-Close 29.34% 4.59% 0.16x Within
2025-11-07 Pre-Market 16.75% 8.85% 0.53x Within
2026-03-03 Pre-Market 180.26% 9.23% 0.05x Within
2026-05-07 After-Close 16.85% 3.05% 0.18x Within
2026-08-06 After-Close 21.19% 4.41% 0.21x Within

Earnings calendar: this week’s reports with expected vs actual moves →

PRME Options Activity & IV Rank

PRME IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 122.2%
7-DTE IV: 146.7%
Expected Move: $1.38
7-DTE Move: $0.93
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 1,946
Put Volume: 1,303
P/C Volume: 0.67
BULLISH
Call OI: 37,734
Put OI: 9,521
P/C OI: 0.252
Total OI: 47,255

ATM Options Pricing

ATM Call: $0.72
ATM Put: $0.65
Call %: 16.9%
Put %: 15.1%

Chain Summary

Chain Volume: 3,249
Chain OI: 47,255
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 64th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
64%
vs own history
GEX tilt
+0.62
OI-weighted, today
Vanna tilt
+0.76
δ-sensitivity to IV
Charm tilt
-0.76
δ-decay vs time
Vanna tilt +0.76: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.76: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 15 ATM contracts, 18k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)22.8LowNov 9
IV Rank (30 DTE)68.6MediumNov 9

Embed PRME IV rank

PRME's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$1.38Nov 9
Beta Analysis

Risk Metrics

Beta: 2.2816
Alpha: 24.77%
Correlation: 0.3402
R-Squared: 11.6%
Stock Volatility: 92.2%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

PRME Institutional Ownership (13F)

Filings for 2026-06-30 · 58 already for 2026-09-30
Diluted shares outstanding: 165,895,706 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

186 filers107,158,365 shares$379.60M value64.59% of float
# Filer Shares Value % of Total % of Float Period
1 Alphabet Inc. 16,562,498 $50.68M 13.35% 9.98% 2026-09-30
2 BlackRock, Inc. Custodian 9,602,041 $35.43M 9.33% 5.79% 2026-06-30
3 ARK Investment Management LLC 8,348,746 $30.81M 8.12% 5.03% 2026-06-30
4 State Street Corp 7,576,460 $27.96M 7.36% 4.57% 2026-06-30
5 T. Rowe Price Investment Management, Inc. 5,237,332 $19.33M 5.09% 3.16% 2026-06-30
6 Vanguard Capital Management LLC 4,522,640 $16.69M 4.40% 2.73% 2026-06-30
7 Balyasny Asset Management L.P. 3,969,082 $14.65M 3.86% 2.39% 2026-06-30
8 Goldman Sachs Group Inc Custodian 3,430,518 $12.66M 3.33% 2.07% 2026-06-30
9 Casdin Capital, LLC 3,167,175 $11.69M 3.08% 1.91% 2026-06-30
10 Woodline Partners LP 3,003,904 $11.08M 2.92% 1.81% 2026-06-30
11 UBS Group AG Custodian 2,794,689 $10.31M 2.72% 1.68% 2026-06-30
12 Sumitomo Mitsui Trust Group, Inc. 2,911,596 $8.89M 2.34% 1.76% 2026-09-30
13 Amova Asset Management Americas, Inc. 2,407,018 $8.86M 2.33% 1.45% 2026-06-30
14 Citadel Advisors LLC Custodian 2,054,543 $7.58M 2.00% 1.24% 2026-06-30
15 Geode Capital Management, LLC Custodian 2,452,555 $7.49M 1.97% 1.48% 2026-09-30
16 ADAR1 Capital Management, LLC 1,997,552 $7.37M 1.94% 1.20% 2026-06-30
17 FMR LLC Custodian 1,761,884 $6.50M 1.71% 1.06% 2026-06-30
18 Two Sigma Investments, LP Custodian 1,524,511 $5.63M 1.48% 0.92% 2026-06-30
19 Redmile Group, LLC 1,389,632 $5.13M 1.35% 0.84% 2026-06-30
20 FARALLON CAPITAL MANAGEMENT, L.L.C. 1,240,843 $4.58M 1.21% 0.75% 2026-06-30
21 Jump Financial, LLC 1,240,429 $4.58M 1.21% 0.75% 2026-06-30
22 Bank of America Corp Custodian 981,335 $3.62M 0.95% 0.59% 2026-06-30
23 Vanguard Portfolio Management LLC 961,826 $3.55M 0.94% 0.58% 2026-06-30
24 Charles Schwab Investment Management, Inc. 927,538 $3.42M 0.90% 0.56% 2026-06-30
25 Northern Trust Corp Custodian 912,597 $3.37M 0.89% 0.55% 2026-06-30
5 filers$2.99M notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $868.84K 29.08% 2026-09-30
2 Jane Street Group, LLC Custodian $718.07K 24.03% 2026-06-30
3 Citadel Advisors LLC Custodian $591.14K 19.79% 2026-06-30
4 Susquehanna International Group, LLP Custodian $495.20K 16.57% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $314.39K 10.52% 2026-06-30
5 filers$2.90M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $1.64M 56.42% 2026-06-30
2 Citadel Advisors LLC Custodian $511.80K 17.66% 2026-06-30
3 Jane Street Group, LLC Custodian $285.61K 9.86% 2026-06-30
4 Simplex Trading, LLC Custodian $252.34K 8.71% 2026-09-30
5 GROUP ONE TRADING LLC Custodian $213.28K 7.36% 2026-06-30

PRME Insider Trading (Form 4)

Latest: 2026-06-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-08 David P Schenkein Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Thomas Cahill Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Wendy Chung Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Robert Nelsen Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Jeffrey D Marrazzo Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Kaye I Foster-Cheek Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Michael Aaron Kelly Director Grant (A) +75,000 opt — EDGAR
2026-04-17 Svetlana Ni Makhni Chief Financial Officer Grant (A) +800,000 opt — EDGAR
2026-02-27 Allan Reine Chief Executive Officer Grant (A) +1,300,000 opt — EDGAR
2026-02-24 Ann L. Lee Chief Technical Officer Grant (A) +375,000 opt — EDGAR
2026-02-24 Carman Alenson See Remarks Grant (A) +140,000 opt — EDGAR
2025-08-05 Robert Nelsen Director Mixed — — EDGAR
2025-08-05 Michael Aaron Kelly Director Mixed — — EDGAR
2025-08-05 David P Schenkein Director Mixed — — EDGAR
2025-08-05 Allan Reine Chief Executive Officer Mixed — — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

PRME Insider Holdings

10 insiders · @ $4.30
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 David R. Liu 10%+ Owner 20,240,945 $87.04M $163.0K 7 2025-07-01
2 Robert Nelsen Director 6,128,297 $26.35M $43.60M 8 2026-06-08
3 ARCH Venture Partners X, LLC 10%+ Owner 6,128,297 $26.35M $10.00M 1 2025-08-01
4 ARCH Venture Fund XII, L.P. 10%+ Owner 6,128,297 $26.35M $10.00M 1 2025-08-01
5 Thomas Cahill Director 4,905,679 $21.09M $6.80M 6 2026-06-08
6 GV 2021, L.P. 10%+ Owner 3,262,440 $14.03M -$4.45M 4 2025-08-05
7 Keith Michael Gottesdiener See Remarks 2,361,078 $10.15M $0 8 2025-05-12
8 Allan Reine Chief Executive Officer 125,000 $537.5K $147.2K 9 2026-02-27
9 Ann L. Lee Chief Technical Officer 100,000 $430.0K $113.0K 8 2026-02-24
10 Richard Brudnick Chief Business Officer 20,000 $86.0K $23.8K 6 2025-05-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

PRME Board & Officers

As of SEC filings through Jun 8, 2026

Directors 8

Officers 5

10% owners 17

Changes in the last 10 years (42)
Apr 16, 2026Svetlana Ni Makhni became Chief Financial Officer
Jul 14, 2025The company announced the departure of Jeremy Duffield as Chief Scientific Officer in an SEC filing
May 19, 2025The company announced the departure of Keith Michael Gottesdiener from the board in an SEC filing
May 19, 2025The company announced the departure of Keith Michael Gottesdiener as President and Chief Executive Officer in an SEC filing
May 19, 2025Allan Reine listed as Chief Executive Officer (previously Chief Financial Officer) in SEC filings
May 19, 2025Allan Reine first listed as a director in an SEC filing
Feb 23, 2024Carman Alenson listed as SVP, Finance and Chief Accounting Officer (previously Interim Chief Financial Officer and Chief Accounting Officer) in SEC filings
Feb 20, 2024ARCH Venture Partners XII, LLC first on file as a 10% owner
Feb 20, 2024ARCH Venture Partners XII, L.P. first on file as a 10% owner
Feb 20, 2024ARCH Venture Fund XII, L.P. first on file as a 10% owner
Jan 17, 2024Allan Reine became Chief Financial Officer
May 10, 2023Jeffrey D Marrazzo became a director
May 10, 2023Gv 2021, L.p. first listed as a 10% owner in an SEC filing
May 10, 2023Gv 2021 Gp, L.p. first listed as a 10% owner in an SEC filing
May 10, 2023Gv 2021 Gp, L.l.c. first listed as a 10% owner in an SEC filing
May 10, 2023Alphabet Inc. first listed as a 10% owner in an SEC filing
Oct 19, 2022Wendy Chung became a director
Oct 19, 2022Thomas Cahill became a director
Oct 19, 2022Steven Gillis became a 10% owner
Oct 19, 2022Robert Nelsen became a director
Not reported recently (4)
  • Meredith Goldwasser · Last reported as SVP, Strategy & Corporate Ops. in an SEC filing dated Mar 3, 2025
  • Gv 2019, L.p. · Last reported as a 10% owner in an SEC filing dated Jun 22, 2023
  • Gv 2019 Gp, L.l.c. · Last reported as a 10% owner in an SEC filing dated Jun 22, 2023
  • Gv 2019 Gp, L.p. · Last reported as a 10% owner in an SEC filing dated Jun 22, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

PRME Proposed Insider Sales (Form 144)

Latest: 2023-06-20
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-06-20 Alphabet Holdings LLC 10% Stockholder 522,561 $7.79M 2023-06-20 Raymond James & Associates, Inc. — EDGAR
2023-06-12 Alphabet Holdings LLC 10% Stockholder 159,596 $2.31M 2023-06-12 RAYMOND JAMES & ASSOCIATES — EDGAR
2023-06-05 Alphabet Holdings LLC 10% Stockholder 88,081 $1.42M 2023-06-05 Raymond James & Associates, Inc. — EDGAR
2023-05-30 Alphabet Holdings LLC 10% Stockholder 71,263 $974.2K 2023-05-30 Raymond James & Associates — EDGAR
2023-05-18 Alphabet Holdings LLC 10% Stockholder 260,156 $3.39M 2023-05-18 RAYMOND JAMES & ASSOCIATES INC 10b5-1 EDGAR
2023-05-08 GV 2019, L.P. 10% Stockholder 1,121,197 $16.06M 2023-05-08 RAYMOND JAMES & ASSOCIATES INC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-08-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-08-06 Earnings results EDGAR
2026-07-08 Other events EDGAR
2026-06-08 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-08-06 0001628280-26-053883 EDGAR
ETF Holders
44 ETFs hold PRME
25 shown · $60.05M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.17% $16.7M $10.0B 2026-11-05
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $11.5M $76.6B 2026-11-06
3 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $9.5M — 2026-09-30
4 VXF Vanguard Extended Market ETF Vanguard 0.00% $4.1M — 2026-09-30
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.03% $3.6M $13.7B 2026-11-06
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.03% $3.3M $11.1B 2026-11-06
7 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $2.0M — 2026-08-31
8 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.7M — 2026-09-30
9 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.11% $1.3M $1.2B 2026-11-06
10 VHT Vanguard Health Care ETF Vanguard 0.00% $967,738 — 2026-09-30
11 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $930,846 $93.2B 2026-11-06
12 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.12% $599,798 — 2026-11-06
13 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.00% $551,034 $13.9B 2026-11-06
14 NXTE AXS Green Alpha ETF Nport 0.87% $497,113 — 2026-06-30
15 IDNA iShares Genomics Immunology and Healthcare ETF iShares (BlackRock) 0.12% $430,711 $346.3M 2026-11-06
16 GNOM Global X Genomics & Biotechnology ETF Global X 0.34% $358,273 — 2026-11-06
17 BBC Virtus Biotech Clinical Trials Etf Nport 0.70% $327,052 — 2026-07-31
18 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $326,862 — 2026-08-31
19 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.02% $278,439 — 2026-09-30
20 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.01% $241,755 $4.0B 2026-11-05
21 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $229,471 — 2026-07-31
22 RSSL Global X Russell 2000 ETF Global X 0.01% $211,310 — 2026-11-06
23 SPGM State Street® SPDR® Portfolio MSCI Global Stock Market ETF SPDR (State Street) 0.01% $150,558 $1.7B 2026-11-05
24 GINN Goldman Sachs Innovate Equity ETF Goldman 0.06% $106,497 $173.0M 2026-11-05
25 IBBQ Invesco Nasdaq Biotechnology ETF Invesco 0.05% $62,901 — 2026-11-05
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.08
TTM Revenue
$4.07M
TTM Net Income
$-187.89M
TTM Op. Cash Flow
$-156.05M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$1.15M$-42.11M$-0.24$-41.05M
Q1 '262026-03-31$856.00K$-49.12M$-0.28$-42.71M
Q4 '252025-12-31$838.00K$-46.08M$-0.24$-37.26M
Q3 '252025-09-30$1.23M$-50.58M$-0.32$-35.04M
Q2 '252025-06-30$1.11M$-52.59M$-0.41$-41.41M
Q1 '252025-03-31$1.45M$-51.89M$-0.40$-48.86M
Q4 '242024-12-31$2.18M$-42.28M$-0.31$16.25M
Q3 '242024-09-30$209.00K$-52.52M$-0.44$-25.91M
Q2 '242024-06-30—$-55.33M$-0.46$-45.49M
Q1 '242024-03-31$591.00K$-45.76M$-0.44$-67.71M
Q4 '232023-12-31—$-65.64M$-0.72$-43.86M
Q3 '232023-09-30—$-50.71M$-0.55$-39.17M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
17.92
P/S
175.14
EV/EBITDA
—
EV/Sales
163.49
ROE
-472.0%
ROA
-75.4%
Div Yield
0.00%
FCF Yield
-21.88%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$713.35M
as of 2026-11-09

PRME vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 45.8 +45.5% +30.7% 27
MRNA Moderna, Inc. Common Stock $101.5B — −27.6% +771.7% 53
NTRA Natera, Inc. Common Stock $45.1B — +36.6% +40.0% 43
GH Guardant Health, Inc. Common Stock $20.4B — +42.7% +56.1% 23
TWST Twist Bioscience Corporation Common Stoc $8.0B — +17.8% +317.8% 92
CRSP CRISPR Therapeutics AG $4.9B — −34.3% −6.9% 37
CDNA CareDx, Inc. $4.1B 35.3 +38.9% +341.1% 37
BEAM Beam Therapeutics Inc. Common Stock $2.7B — +163.3% −0.4% 77
PRME Prime Medicine, Inc. Common Stock $843M — −17.9% +21.8% 69
Peer median $14.2B 40.5 +37.8% +48.0% 40

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
32.87M
SI % of Float
34.36%
Days to Cover
5.52
Short Vol Ratio
39.4%
Free Float
95.66M
Float %
52.7%
Short interest 2026-10-15 • Short volume 2026-11-09 • Float 2026-08-14